Fabio Melandro, Riccardo Aurelio Nasto, Michael Ginesini, Emanuele Balzano, Maria Lucia Bindi, Davide Ghinolfi, Quirino Lai
BACKGROUND AND OBJECTIVE: Cholangiocarcinoma (CCA) is the second commonest primary liver malignancy. Nowadays, the only available treatment with curative intent of intrahepatic cholangiocarcinoma (iCCA) is surgical resection, with a 5-year overall survival (OS) of 25-40%. However, recurrence rate remains high. In this comprehensive review, we describe the newest surgical strategies for iCCA management, including vascular resection, the role of mini-invasive surgery, liver transplant, strategies for future liver remnant augmentation, and the role of neoadjuvant therapies...
March 27, 2023: Chinese Clinical Oncology